EASD 2022: Frailest Patients With Type 2 Diabetes Benefit Most From SGLT2 Inhibitors and GLP-1 Receptor Agonists Over DPP4 Inhibitors
These benefits are obtained without an increased risk of adverse events
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.